Q1 EPS Estimate for Elevance Health Boosted by Analyst

Elevance Health, Inc. (NYSE:ELV) – Equities researchers at Leerink Partnrs raised their Q1 2025 earnings estimates for Elevance Health in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings per share of $11.57 for the quarter, up from their prior forecast of $10.97. The consensus estimate for Elevance Health’s current full-year earnings is $33.96 per share. Leerink Partnrs also issued estimates for Elevance Health’s Q2 2025 earnings at $10.17 EPS, Q2 2026 earnings at $11.83 EPS, FY2028 earnings at $54.20 EPS and FY2029 earnings at $62.23 EPS.

Elevance Health (NYSE:ELV) last announced its earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%.

A number of other research firms have also recently commented on ELV. Truist Financial lifted their price target on Elevance Health from $480.00 to $510.00 and gave the stock a “buy” rating in a report on Friday, April 11th. StockNews.com raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Thursday, March 20th. Robert W. Baird reaffirmed a “neutral” rating and set a $529.00 target price (down previously from $625.00) on shares of Elevance Health in a report on Tuesday. Stephens downgraded shares of Elevance Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $520.00 to $440.00 in a research report on Wednesday, January 22nd. Finally, Guggenheim started coverage on Elevance Health in a report on Wednesday, April 9th. They set a “buy” rating and a $518.00 price objective for the company. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $514.41.

Elevance Health Price Performance

NYSE:ELV opened at $424.44 on Friday. The stock has a market capitalization of $96.09 billion, a PE ratio of 16.57, a P/E/G ratio of 1.18 and a beta of 0.77. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. The firm has a fifty day simple moving average of $416.11 and a 200 day simple moving average of $411.67. Elevance Health has a 1-year low of $362.21 and a 1-year high of $567.26.

Institutional Investors Weigh In On Elevance Health

Hedge funds have recently added to or reduced their stakes in the business. Insigneo Advisory Services LLC increased its holdings in Elevance Health by 12.8% in the first quarter. Insigneo Advisory Services LLC now owns 861 shares of the company’s stock valued at $375,000 after purchasing an additional 98 shares during the period. Demars Financial Group LLC acquired a new stake in Elevance Health during the 1st quarter valued at approximately $89,865,000. AA Financial Advisors LLC raised its holdings in Elevance Health by 20.9% during the 1st quarter. AA Financial Advisors LLC now owns 792 shares of the company’s stock worth $344,000 after purchasing an additional 137 shares during the last quarter. Grove Bank & Trust lifted its position in shares of Elevance Health by 1.4% in the 1st quarter. Grove Bank & Trust now owns 2,612 shares of the company’s stock worth $1,136,000 after purchasing an additional 37 shares during the period. Finally, Grimes & Company Inc. acquired a new stake in shares of Elevance Health during the first quarter worth $201,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Elevance Health news, CAO Ronald W. Penczek sold 443 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $415.13, for a total transaction of $183,902.59. Following the sale, the chief accounting officer now owns 1,847 shares of the company’s stock, valued at approximately $766,745.11. The trade was a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total value of $1,388,635.20. Following the completion of the transaction, the executive vice president now owns 10,116 shares of the company’s stock, valued at $4,008,970.80. The trade was a 25.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.29% of the stock is currently owned by corporate insiders.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th were issued a $1.71 dividend. The ex-dividend date was Monday, March 10th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.61%. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. Elevance Health’s dividend payout ratio is 26.71%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.